Isomorphic Labs raises $2.1B to scale AI drug discovery and push pipeline toward clinic

Isomorphic Labs secured a massive $2.1 billion Series B round led by Thrive Capital to scale its AI drug discovery model and advance its therapeutics pipeline. The financing is positioned as a major reinforcement of Isomorphic’s integrated approach, built around its proprietary drug-design engine (IsoDDE), rather than a licensable software stack. The funding comes as the company seeks to accelerate development toward clinical testing while expanding its teams across AI, engineering, drug design, and clinical development. Isomorphic also maintains partnerships with large pharma players including Novartis, Eli Lilly, and Johnson & Johnson.